These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 35733370)

  • 1. Thrombotic and Hemorrhagic Issues Associated with Myeloproliferative Neoplasms.
    Papageorgiou L; Elalamy I; Vandreden P; Gerotziafas GT
    Clin Appl Thromb Hemost; 2022; 28():10760296221097969. PubMed ID: 35733370
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thrombotic and bleeding complications in classical myeloproliferative neoplasms.
    McMahon B; Stein BL
    Semin Thromb Hemost; 2013 Feb; 39(1):101-11. PubMed ID: 23264112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Platelets as Mediators of Thromboinflammation in Chronic Myeloproliferative Neoplasms.
    Marin Oyarzún CP; Heller PG
    Front Immunol; 2019; 10():1373. PubMed ID: 31258539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. From Budd-Chiari syndrome to acquired von Willebrand syndrome: thrombosis and bleeding complications in the myeloproliferative neoplasms.
    Stein BL; Martin K
    Hematology Am Soc Hematol Educ Program; 2019 Dec; 2019(1):397-406. PubMed ID: 31808903
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular biomarkers of thrombosis in myeloproliferative neoplasms.
    Barbui T; Falanga A
    Thromb Res; 2016 Apr; 140 Suppl 1():S71-5. PubMed ID: 27067982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pathogenesis of thrombotic and hemorrhagic complications in myeloproliferative and myelodysplastic syndromes].
    Vlădăreanu AM; Popov V; Bumbea H; Ciufu C; Vasilache V; Petre A; Onisâi M
    Rev Med Chir Soc Med Nat Iasi; 2011; 115(1):14-9. PubMed ID: 21688554
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence and clinical risk factors for bleeding and thrombotic complications in myeloproliferative disorders. A retrospective analysis of 260 patients.
    Wehmeier A; Daum I; Jamin H; Schneider W
    Ann Hematol; 1991 Aug; 63(2):101-6. PubMed ID: 1912029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. From Budd-Chiari syndrome to acquired von Willebrand syndrome: thrombosis and bleeding complications in the myeloproliferative neoplasms.
    Stein BL; Martin K
    Blood; 2019 Nov; 134(22):1902-1911. PubMed ID: 31778549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The paradox of platelet activation and impaired function: platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera.
    Michiels JJ; Berneman Z; Schroyens W; Finazzi G; Budde U; van Vliet HH
    Semin Thromb Hemost; 2006 Sep; 32(6):589-604. PubMed ID: 16977569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Propensity for hemorrhage and thrombosis in chronic myeloproliferative disorders.
    Kessler CM
    Semin Hematol; 2004 Apr; 41(2 Suppl 3):10-4. PubMed ID: 15190517
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnosis, prevention, and management of bleeding episodes in Philadelphia-negative myeloproliferative neoplasms: recommendations by the Hemostasis Working Party of the German Society of Hematology and Medical Oncology (DGHO) and the Society of Thrombosis and Hemostasis Research (GTH).
    Appelmann I; Kreher S; Parmentier S; Wolf HH; Bisping G; Kirschner M; Bergmann F; Schilling K; Brümmendorf TH; Petrides PE; Tiede A; Matzdorff A; Griesshammer M; Riess H; Koschmieder S
    Ann Hematol; 2016 Apr; 95(5):707-18. PubMed ID: 26916570
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship of thrombohemorrhagic complications to endothelial cell function in patients with chronic myeloproliferative disorders.
    Friedenberg WR; Roberts RC; David DE
    Am J Hematol; 1992 Aug; 40(4):283-9. PubMed ID: 1503083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The pathobiology of thrombosis, microvascular disease, and hemorrhage in the myeloproliferative neoplasms.
    Hasselbalch HC; Elvers M; Schafer AI
    Blood; 2021 Apr; 137(16):2152-2160. PubMed ID: 33649757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. JAK2V617F-positive endothelial cells contribute to clotting abnormalities in myeloproliferative neoplasms.
    Etheridge SL; Roh ME; Cosgrove ME; Sangkhae V; Fox NE; Chen J; López JA; Kaushansky K; Hitchcock IS
    Proc Natl Acad Sci U S A; 2014 Feb; 111(6):2295-300. PubMed ID: 24469804
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thrombosis and hemorrhage in myeloproliferative neoplasms: The platelet perspective.
    Feng Y; Zhang Y; Shi J
    Platelets; 2022 Oct; 33(7):955-963. PubMed ID: 35081860
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Practical management of the haemorrhagic complications of myeloproliferative neoplasms.
    Jones E; Dillon B; Swan D; Thachil J
    Br J Haematol; 2022 Nov; 199(3):313-321. PubMed ID: 35724983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thrombotic, Vascular, and Bleeding Complications of the Myeloproliferative Neoplasms.
    Schafer AI
    Hematol Oncol Clin North Am; 2021 Apr; 35(2):305-324. PubMed ID: 33641871
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic dilemmas: balancing the risks of bleeding, thrombosis, and leukemic transformation in myeloproliferative disorders (MPD).
    Murphy S
    Thromb Haemost; 1997 Jul; 78(1):622-6. PubMed ID: 9198227
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thrombotic disease in the myeloproliferative neoplasms.
    Falanga A; Marchetti M
    Hematology Am Soc Hematol Educ Program; 2012; 2012():571-81. PubMed ID: 23233637
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical Analysis of Gene Mutation and Vascular Events in Patients with BCR/ABL Negative Myeloproliferative Neoplasms].
    Hu BD; Chen L
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Jun; 30(3):813-818. PubMed ID: 35680810
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.